News - Licensing, UCB

Filter

Current filters:

LicensingUCB

Popular Filters

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

UCB links with UK’s MRC Technology for a fibrosis program

UCB links with UK’s MRC Technology for a fibrosis program

13-02-2014

Belgium’s leading drugmaker UCB and UK’s MRC Technology have entered an exclusive license agreement,…

LicensingPharmaceuticalResearchUCB

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Oncodesign and UCB enter into collaboration for development of Nanocyclix in neurodegenerative diseases

13-11-2013

French drug discovery company Oncodesign has entered into a research collaboration and exclusive license…

BiotechnologyEuropeLicensingNeurologicalOncodesignUCB

Biotie completes planned portfolio review

Biotie completes planned portfolio review

24-09-2013

Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

04-07-2013

Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…

Anti-Arthritics/RheumaticsLicensingolokizumabPharmaceuticalR-PharmaRoActemraRocheUCB

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie

27-02-2013

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium's…

Biotie TherapiesLicensingNeurologicalPharmaceuticaltozadenantUCB

UCB links with ConfometRX for neuroscience research

24-02-2013

Belgium's largest drugmaker UCB (Euronext Brussels: UCB) has signed a research agreement with California,…

ConfometRXLicensingNeurologicalPharmaceuticalResearchUCB

UCB reports 5% lift in first nine-month sales

29-10-2012

Belgium's largest pharma company, UCB (UCB: BR), has reported interim results for the first nine months…

FinancialLicensingolokizumabPharmaceuticalUCB

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

UCB pulls out of Biotie partnership on SYN118

25-11-2011

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that, as it had already expected following disappointing…

Biotie TherapiesLicensingNeurologicalPharmaceuticalUCB

Back to top